Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Susanne Hamann"'
Autor:
Sebastian Maasberg, Ulrich-Frank Pape, Christian Fottner, Peter E. Goretzki, Martin Anlauf, Dieter Hörsch, Birgit Cremer, Dominik M. Schulte, Detlef Quietzsch, Frank Scheerer, Gabriele Pöpperl, Thorsten D. Poeppel, Nehara Begum, Christian Grohé, Anja Rinke, Ursula Plöckinger, Betram Wiedenmann, Rudolf Arnold, Peter Neuhaus, Wolfram H. Knapp, Hendrick Lehnert, Christoph Auernhammer, Marianne Pavel, Ludwig Fischer von Weikersthal, Bernd Schmidt, Harald H. Klein, Markus Essler, Jörg-Dietrich Neumann, Susanne Hamann, Frank Steffens, Frank Demtröder, Anke Kröcher, Flavius Zoicas, Harald Lahner, Frank Weber, Michael Geißler, Andreas Raffel, Markus Krausch, Patrick Zimmermann, Markus M. Lerch, Thomas Wirth, Matthias Lang, Samer Ezziddin, Frank Lammert, Marina Bischoff, Annelore Altendorf-Hofmann, Lothar Müller, Albrecht Hoffmeister, Silke Klose, Thomas J. Musholt, Stefan Post, Ralf Gertler, Hubert Scheuerlein, Tanja Bergmann, Guido Bisping, Andreas Knauerhase, Bernhard Rendenbach, Volker Groß, Michael Scheurlen, Heiner Mönig, Theodor Kudlich, Patricia Grabowski, Felix Watza, Klemens Scheidhauer, Elke Möbius
Publikováno v:
Onkologische Welt. 10:182-192
ZusammenfassungNeuroendokrine Neoplasien (NEN) umfassen eine seltene Tumorentität mit heterogener Biologie, Prognose und therapeutischen Optionen. In Zusammenhang mit der kürzlichen Publikation der ersten deutschen Leitlinie zur Diagnostik und Ther
Autor:
Robert P. Jones, Graeme J. Poston, Susanne Hamann, Gunnar Folprecht, Hassan Malik, Stephen W. Fenwick
Publikováno v:
European journal of cancer (Oxford, England : 1990). 50(9)
Aims Long-term survival has been demonstrated for patients with irresectable colorectal liver metastases who are brought to resection by chemotherapy. However, it remains unclear whether improved long-term outcome seen with modern therapies translate
Autor:
Susanne Hamann, Nicola Gökbuget, Markus Schaich, Gerhard Ehninger, Kalina Ramadanova, Ulrike Reuner, Hansjörg Hoff
Publikováno v:
Annals of Hematology. 89:221-223
Autor:
R. Ehrenberg, Klaus Mross, C.-H. Köhne, Gunnar Folprecht, Susanne Hamann, J. Kuhlmann, Martin Kornacker, Dirk Strumberg, Beate Schultheis, R. Fischer, O. Boix, Jürgen Krauss, John Lettieri, U. T. Hacker
Publikováno v:
Annals of Oncology
Background Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan. The multitargeted kinase inhibitor, regorafenib, was combined with chemotherapy as first- or second-line treatment of
Publikováno v:
International Journal of Mass Spectrometry and Ion Processes. 137:43-54
Ionic gas-phase reactions of chloro- and bromoanisoles with CH 3NH 2 and (CH 3) 2NH via radical cations were investigated by FT-ICR spectrometry using an external ion source. Protonated N-methylanisidines are formed quantitatively from bromoanisole r
Autor:
Conny Höflich, Susanne Hamann, Jan M. Langrehr, Sven Schmidt, Peter Neuhaus, Jens Mittler, Dictmar Jacob
Publikováno v:
Journal of hepato-biliary-pancreatic surgery. 14(5)
Major abdominal surgery such as liver resection is associated with an excessive hyperinflammatory response and transient immunosuppression. We investigated the immunomodulating effect of preoperative pulse administration of high-dose methylprednisolo
Autor:
Jan Kuhlmann, K. Mross, Dirk Strumberg, T. Lin, U. T. Hacker, O. Boix, Jürgen Krauss, Beate Schultheis, Susanne Hamann, R. Fischer, Martin Kornacker, R. Ehrenberg, C.-H. Köhne, Gunnar Folprecht
Publikováno v:
Journal of Clinical Oncology. 29:3585-3585
3585 Background: Regorafenib is an oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, B-RAF). Regorafenib resulted in a 74% disease...
Autor:
Sven C. Schmidt, Susanne Hamann, Jan M. Langrehr, Conny Höflich, Jens Mittler, Dictmar Jacob, Peter Neuhaus
Publikováno v:
Journal of Hepato -- Biliary -- Pancreatic Surgery; Sep2007, Vol. 14 Issue 5, p484-492, 9p
Autor:
Tanja Trarbach, Gerhard Ehninger, Jan Stoehlmacher-Williams, Susanne Hamann, Gunnar Folprecht, Katharina Schütte
Publikováno v:
BMC Cancer
Background The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival compared to FOLFIRI in patients with metastatic colorectal cancer (mCRC). Adding cetuximab to FOLFO